Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00210
|
|||||
| Drug Name |
Alprostadil
|
|||||
| Synonyms |
(11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid; (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid; (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate; (13E,15S)-11alpha,15-dihydroxy-9-oxoprost-13-en-1-oic acid; 7-[(1R,2R,3R)-3-hydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]-5-oxocyclopentyl]heptanoic acid; Alista; Alprostadil (JP15/USP/INN); Alprostadil Prostoglandin E1; Alprostadilum; Alprox-TD; BML1-F06; Befar; Befar (TN); Caverject; Caverject (TN); Edex; Edex (TN); FemLife; Femprox; HEI-507; L-Prostaglandin E1; MR 256; MR-256; Muse; Muse (TN); PGE1; PGE1 Oligomer; Prink; Prink (TN); Prost-13-en-1-oic acid, 11,15-dihydroxy-9-oxo-, (11alpha,13E,15S)-, homopolymer; Prostaglandin E1; Prostavasin; Prostin VR; Prostin VR Pediatric; Prostin VR pediatric (TN); RayVa; Sugiran; Topiglan; U-10136; Viridal; Vitaros
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Erectile dysfunction [ICD11:HA01] | Approved | [1] | |||
| Therapeutic Class |
Vasodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C20H34O5
|
|||||
| Canonical SMILES |
CCCCCC(C=CC1C(CC(=O)C1CCCCCCC(=O)O)O)O
|
|||||
| InChI |
InChI=1S/C20H34O5/c1-2-3-6-9-15(21)12-13-17-16(18(22)14-19(17)23)10-7-4-5-8-11-20(24)25/h12-13,15-17,19,21,23H,2-11,14H2,1H3,(H,24,25)/b13-12+/t15-,16+,17+,19+/m0/s1
|
|||||
| InChIKey |
GMVPRGQOIOIIMI-DWKJAMRDSA-N
|
|||||
| CAS Number |
CAS 745-65-3
|
|||||
| Pharmaceutical Properties | Molecular Weight | 354.5 | Topological Polar Surface Area | 94.8 | ||
| Heavy Atom Count | 25 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 5 | |||
| XLogP |
3.2
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103171219
,103914567
,12013405
,14901054
,14901056
,24887977
,24890439
,24898661
,24898855
,24898994
,26719695
,26752225
,26752226
,3139926
,39289772
,4266050
,46386879
,46386882
,46387002
,47216549
,47515087
,47515088
,47810514
,47959471
,48110217
,48184750
,48415538
,49681576
,49699251
,50104916
,50104917
,53790811
,57357853
,57654538
,7312
,77812073
,7847248
,7978676
,8143220
,85789478
,8616376
,91702047
,92126041
,92308647
,92309224
,92309904
,92712130
,93166905
,99300818
,99302336
|
|||||
| ChEBI ID |
ChEBI:15544
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MRP4 | Transporter Info | Multidrug resistance-associated protein 4 | Substrate | [2] | |
| OAT1 | Transporter Info | Organic anion transporter 1 | Substrate | [3] | ||
| OATP2A1 | Transporter Info | Organic anion transporting polypeptide 2A1 | Substrate | [4] | ||
| OATP3A1 | Transporter Info | Organic anion transporting polypeptide 3A1 | Substrate | [5] | ||
| Drug-Transporter Activity Data | ||||||
| Drug-Transporter Activity Data | MRP4 | Transporter Info | Km =2.1 microM | Spodoptera frugiperda (Sf9) cells-MRP4 | [2] | |
| OATP3A1 | Transporter Info | Km =0.0485 microM | Oocytes-OATP3A1 | [5] | ||
| References | ||||||
| 1 | Alprostadil was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal antiinflammatory drugs. Proc Natl Acad Sci U S A. 2003 Aug 5;100(16):9244-9. | |||||
| 3 | Prostaglandin transporter (OATP2A1/SLCO2A1) contributes to local disposition of eicosapentaenoic acid-derived PGE3. Prostaglandins Other Lipid Mediat. 2016 Jan;122:10-7. | |||||
| 4 | Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA(hPGT). J Clin Invest. 1996 Sep 1;98(5):1142-9. | |||||
| 5 | Molecular characterization of human and rat organic anion transporter OATP-D. Am J Physiol Renal Physiol. 2003 Dec;285(6):F1188-97. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.